A Future Without Celiac Disease
Investing in detection, prevention, and curative breakthroughs
Investing in Breakthroughs for Celiac Disease
We invest in high-impact diagnostics, therapeutics, and enabling technologies that address the most urgent unmet needs in celiac disease. Our portfolio focuses on scalable, science-driven innovations that improve early detection, advance disease-modifying treatments, and enhance long-term patient outcomes. By targeting ventures with strong scientific foundations and clear development pathways, we position capital to deliver both measurable health impact and financial returns.
Capital. Discipline. Impact.
We back bold leaders and breakthrough ideas, turning promising research into real solutions for millions living with celiac disease. By providing capital, connections, and reinvesting returns into new initiatives, we accelerate the path from discovery to life-changing treatments.
Patient Focus as Strategic Advantage
Our direct engagement with the global celiac community provides real-time intelligence on unmet clinical needs, treatment priorities, and adoption pathways. This patient-centered insight strengthens investment diligence, informs portfolio strategy, and reduces translational risk by aligning innovation with demonstrated demand. We invest in solutions designed for real-world impact from the outset
A Proprietary Pipeline Built on Global Leadership
Our investment strategy is powered by a global ecosystem of clinicians, researchers, and regulatory leaders at the forefront of celiac science. This network provides early access to emerging discoveries, expert scientific evaluation, and accelerated pathways from research to commercialization. The result is differentiated deal flow and a structural advantage in identifying and advancing high-potential opportunities.
~110M
People with
celiac disease globally
50%
Diagnosed patients who still report symptoms while on gluten-free diet
$30B+
Estimated global economic burden annually
2x/4x
Increased risk of coronary artery disease/small bowel cancers
Celiac Disease By The Numbers
Science-Driven, Disciplined Capital Allocation
Each investment undergoes rigorous scientific and commercial evaluation supported by expert advisors across biotechnology, clinical medicine, and regulatory strategy. We prioritize milestone-based funding, capital efficiency, and active portfolio engagement to accelerate translation from discovery to market. Our disciplined approach balances risk with long-term value creation, focusing on ventures with clear development and exit pathways.
Capital Model Designed for Compounding Impact
We operate a venture philanthropy model that reinvests financial returns into new high-potential opportunities, creating a self-reinforcing cycle of innovation. This approach has catalyzed major breakthroughs in other disease areas and enables us to continuously expand the celiac innovation ecosystem. Investors and partners join a scalable platform designed to compound both financial returns and global health impact.
